Novo Nordisk

Growth, value, or both? Healthcare industry stocks are traditionally good hedges against technology and other growth stocks, because they tend to perform well...

Novo Nordisk (NYSE:NVO) has taken legal action against Hims & Hers over compounded versions of its Wegovy pill that do not have individual FDA approval. The FD...

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper...

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S (NVO) has completed a phase 3 study titled “Efficacy and Safety of Ora...

Berenberg lowered the firm’s price target on Novo Nordisk (NVO) to DKK 360 from DKK 415 and keeps a Buy rating on the shares. Published first on TheFly – the u...

Novo Nordisk A/S (NYSE:NVO) plans to start selling its blockbuster obesity drug Wegovy in vials, marking its latest effort to strengthen its position against ri...

Options trades to play for a short squeeze in Hims & Hers as the pain piles up Hims & Hers has been clobbered over the past week as the telehealth company step...

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Novo Nordisk (NVO) has completed a phase 2 trial titled “Effects of NNC0194-0499 Alone...

Key Points Eli Lilly and Novo Nordisk dominate the weight loss drug market, one that soon may approach $100 billion. One of these players has recently gained...

Novo Nordisk (NYSE:NVO) has filed a broad lawsuit against Hims & Hers, seeking to stop sales of compounded and unapproved alternatives to its obesity drug Wegov...